EYES - Second Sight rises on FDA approval for retinal prosthesis system

Second Sight Medical Products (EYES) has climbed ~47.6% in the premarket after the company announced that the FDA has approved Argus 2s retinal prosthesis system.On electrical stimulation, the system bypasses the defunct retinal cells to stimulate remaining viable cells to induce visual perception in those with severe to profound RP, the company said.The timeline on the production of newly approved hardware is subject to the completion of Second Sight’s planned business combination with Pixium Vision which is currently in progress.The redesigned set of external hardware (glasses and video processing unit) will initially be used in combination with previously implanted Argus II systems in the treatment of RP (retinitis pigmentosa).Second Sight anticipates adapting the Argus 2s as the external system for the next generation Orion Visual Cortical Prosthesis System which is currently undergoing development.In 2019, the company announced positive data from six blind patients receiving its Orion Visual Cortical Prosthesis System.

For further details see:

Second Sight rises on FDA approval for retinal prosthesis system